07:00 , Aug 22, 2016 |  BC Week In Review  |  Financial News

Activate Immunotherapy completes venture financing

Activate Immunotherapy, San Diego, Calif.   Business: Cancer   Date completed: 2016-08-15   Type: Venture financing   Raised: Not disclosed   Note: The amount raised is not disclosed.   ...
07:00 , Sep 30, 2013 |  BC Week In Review  |  Clinical News

Lucanix belagenpumatucel-L: Phase III data

The double-blind, international Phase III STOP trial in 532 patients with stage III/IV NSCLC who have responded to or have stable disease following 1 regimen of first-line platinum-based chemotherapy showed that once-monthly intradermal Lucanix plus...
02:15 , Sep 27, 2013 |  BC Extra  |  Clinical News

NovaRx's Lucanix misses NSCLC endpoint

NovaRx Corp. (San Diego, Calif.) said Lucanix belagenpumatucel-L plus best supportive care (BSC) as maintenance therapy missed the primary endpoint of improving median overall survival (OS) vs. placebo plus BSC in the Phase III STOP...
07:00 , Jul 2, 2012 |  BioCentury  |  Finance

3Q Financial Markets Preview: Miles of milestones

A deep line-up of milestones could help retain gains the sector has been holding onto since 1Q12. In particular, investors would love to see further breakthroughs in difficult areas such as Alzheimer's disease and obesity. Top...
07:00 , Jun 18, 2012 |  BioCentury  |  Product Development

Immune springboard

A spate of Phase III data events over the next two years will give a readout on how correctly the lessons learned five years ago about cancer immunotherapies targeting T cell responses have been put...
07:00 , Sep 13, 2010 |  BC Week In Review  |  Company News

Ocimum management update

Ocimum Biosolutions Ltd., Hyderabad, India   Business: Supply/Service, Bioinformatics, Microarrays   Hired: Norrie Russell as president of Ocimum's Gene Logic subsidiary, formerly president and COO of NovaRx Corp.   ...
08:00 , Nov 16, 2009 |  BC Week In Review  |  Clinical News

Lucanix: Phase III amended

NovaRx said FDA approved an amended SPA for the ongoing double-blind, international Phase III STOP trial evaluating best supportive care plus monthly intradermal injections of Lucanix or placebo. The study was designed to enroll a...
07:00 , Apr 20, 2009 |  BioCentury  |  Product Development

Phase III cancer vaccines

Phase III cancer vaccines Company Product Description Indication Status Antigenics Inc. (NASDAQ:AGEN) Oncophage vitespen Heat shock protein vaccine purified from autologous tumor cells Renal cancer Ph...
08:00 , Dec 8, 2008 |  BC Week In Review  |  Company News

NovaRx management update

NovaRx Corp., San Diego, Calif.   Business: Cancer   Hired: Norrie Russell as president and COO, formerly president and CEO of Kalos Therapeutics Inc.   Transitioned: Executive Vice Chairman Habib Fakhrai to CSO   ...
01:12 , Dec 5, 2008 |  BC Extra  |  Company News

NovaRx names Russell president

Cancer company NovaRx (San Diego, Calif.) hired Norrie Russell as president and COO. Previously, he was president and CEO of Kalos (San Diego, Calif.). NovaRx Executive Vice Chairman Habib Fakhrai will become CSO....